vosoritide
Trade name: Voxzogo
PeptideapprovedOrphan Drug FDA
Approved
Nov 19, 2021
Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia, a genetic condition that causes severely short stature and disproportionate growth. — Wikipedia
Clinical trial activity
8 trials · 4 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started May 1, 2020 (NCT04219007)
Timeline
2010s
- Jan 17, 2013
Orphan Drug Designation
Indications
Approved for
Mechanism of action
- Fibroblast growth factor receptor 3ANTAGONIST
FGFR3 antagonist
- Atrial natriuretic peptide receptor BBINDING AGENT
Atrial natriuretic peptide receptor B binding agent
Approval history
- approvedPriority reviewAcceleratedNov 19, 2021
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
First in class
Sources
- ChEMBLCHEMBL3707276 ↗
- WikipediaVosoritide ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07126262 | Phase 2 | Jul 30, 2025 | Biomarin, ICON |
| NCT07073014 | Phase 3 | Jun 20, 2025 | Biomarin |
| NCT06668805 | Phase 2 | Nov 30, 2024 | Biomarin |
| NCT06382155 | Phase 2 | Sep 30, 2024 | Biomarin |
| NCT05849389 | Phase 2 | Jul 31, 2024 | Georgetown University |
| NCT06455059 | Phase 3 | Jun 1, 2024 | Biomarin |
| NCT04554940 | Phase 2 | Oct 10, 2020 | Biomarin |
| NCT04219007 | Phase 2 | May 1, 2020 | Children's National Medical Center |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biomarin | For profit | 6 | 6 | 2 | 2020 |
| Children's National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| ICON | For profit | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1